XTX Topco Ltd Sells 8,263 Shares of Bullfrog AI Holdings, Inc. (NASDAQ:BFRG)

XTX Topco Ltd decreased its holdings in Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) by 44.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,317 shares of the company’s stock after selling 8,263 shares during the period. XTX Topco Ltd owned 0.12% of Bullfrog AI worth $30,000 at the end of the most recent quarter.

Separately, Renaissance Technologies LLC purchased a new stake in Bullfrog AI during the second quarter valued at approximately $34,000. Hedge funds and other institutional investors own 0.96% of the company’s stock.

Bullfrog AI Stock Performance

Shares of Bullfrog AI stock opened at $2.09 on Monday. The stock has a market cap of $18.21 million, a price-to-earnings ratio of -2.46 and a beta of -0.02. The stock has a 50 day moving average price of $2.33 and a 200-day moving average price of $2.42. Bullfrog AI Holdings, Inc. has a one year low of $1.43 and a one year high of $8.35.

Insiders Place Their Bets

In other Bullfrog AI news, CEO Vininder Singh sold 14,405 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $2.65, for a total value of $38,173.25. Following the completion of the sale, the chief executive officer now owns 2,478,041 shares of the company’s stock, valued at $6,566,808.65. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 31,603 shares of company stock valued at $82,989 over the last three months. 33.90% of the stock is owned by company insiders.

Bullfrog AI Profile

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.